Mark Nicolls

Publication Details

  • LFA-1 (CD11a) as a therapeutic target AMERICAN JOURNAL OF TRANSPLANTATION Nicolls, M. R., Gill, R. G. 2006; 6 (1): 27-36

    Abstract:

    Leukocyte function associated antigen-1 (LFA-1) was one of the earliest of cell-surface molecules identified by monoclonal antibodies generated against leukocyte immunogens. This integrin heterodimer is perhaps best known as a classic adhesion molecule facilitating the interaction between T cells and antigen-presenting cells. However, varied studies indicate that LFA-1 has multi-faceted roles in the immune response including adhesion, activation and trafficking of leukocyte populations. While there has been long-standing interest in LFA-1 as a therapeutic target for regulating immunity, anti-LFA-1 therapy is still not a first-line indication for any clinical condition. Antagonism of LFA-1 with monoclonal antibodies, either alone or in combination with other agents, can result in regulatory tolerance in vivo. Furthermore, new generation humanized anti-LFA-1 monoclonal antibodies (Efalizumab) show at least modest promise for continued application in clinical trials. Thus, anti-LFA-1 forms a potential, but still largely unexploited, immunotherapy which may find its greatest application as an agent which augments other therapies.

    View details for DOI 10.1111/j.1600-6143.2005.01158.x

    View details for Web of Science ID 000234344900008

    View details for PubMedID 16433753

Stanford Medicine Resources:

Footer Links: